<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725422</url>
  </required_header>
  <id_info>
    <org_study_id>1232</org_study_id>
    <nct_id>NCT04725422</nct_id>
  </id_info>
  <brief_title>CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)</brief_title>
  <acronym>CHOIR</acronym>
  <official_title>CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Children's Hospital, Boston, MA, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital for Special Surgery, New York City, NY, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Riley Children's Hospital, Indianapolis, IN, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill, NC, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Children's Hospital, Melbourne, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hacettepe University, Ankara, Turkey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bambino Gesù Children's Hospital, Rome, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia, Vancouver, BC, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meyer Children's Hospital, Florence, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to establish a prospective disease registry for chronic&#xD;
      recurrent multifocal osteomyelitis (CRMO)/chronic nonbacterial osteomyelitis (CNO) in order&#xD;
      to investigate the natural history of the disease and the responses of patients to different&#xD;
      clinical managements over 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 2050</completion_date>
  <primary_completion_date type="Anticipated">August 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The change of CNO disease activity score</measure>
    <time_frame>3-6 months</time_frame>
    <description>Disease activity score is calculated as the sum of number of clinical lesion count, patient global assessment (0-10), physician global assessment (0-10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of CNO lesions on MRI</measure>
    <time_frame>3-6 months</time_frame>
    <description>The total number of CNO lesions from MRI as previously described (Zhao, et al. J Rheum 2019) will be used to monitor response in a subset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety monitoring</measure>
    <time_frame>5 years</time_frame>
    <description>Serious adverse events including infections that require IV antibiotics, malignancy, hematological, hepatic, dermatological side effects will be reported</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Chronic Nonbacterial Osteomyelitis</condition>
  <condition>Chronic Recurrent Multifocal Osteomyelitis</condition>
  <arm_group>
    <arm_group_label>disease modifying anti-rheumatic drug, DMARD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>tumor necrosis factor inhibitor, TNFi</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>bisphosphonate</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs</description>
    <arm_group_label>disease modifying anti-rheumatic drug, DMARD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <description>second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs</description>
    <arm_group_label>disease modifying anti-rheumatic drug, DMARD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide</intervention_name>
    <description>second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs</description>
    <arm_group_label>disease modifying anti-rheumatic drug, DMARD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamidronate</intervention_name>
    <description>second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs</description>
    <arm_group_label>bisphosphonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs</description>
    <arm_group_label>bisphosphonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs</description>
    <arm_group_label>tumor necrosis factor inhibitor, TNFi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs</description>
    <arm_group_label>tumor necrosis factor inhibitor, TNFi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab</intervention_name>
    <description>second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs</description>
    <arm_group_label>tumor necrosis factor inhibitor, TNFi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs</description>
    <arm_group_label>tumor necrosis factor inhibitor, TNFi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs</description>
    <arm_group_label>tumor necrosis factor inhibitor, TNFi</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with a diagnosis of CNO/CRMO who have failed NSAIDs and/or with active spinal&#xD;
        lesion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Age at enrollment is equal to or younger than 21 years of age&#xD;
&#xD;
          -  Presence of bone edema on STIR or T2 fat saturation sequence on MRI within 12 weeks of&#xD;
             enrollment&#xD;
&#xD;
          -  Whole body imaging evaluation (either WB MRI or bone scintigraphy)&#xD;
&#xD;
          -  Bone biopsy to exclude infection or malignancy unless bone lesions follow typical&#xD;
             distribution or there is IBD, psoriasis, or palmar plantar pustulosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - History of or current malignancy&#xD;
&#xD;
          -  Current infectious osteomyelitis&#xD;
&#xD;
          -  Contraindication to the selected treatment agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongdong (Dan) Zhao, MD, PhD</last_name>
    <phone>206-987-2000</phone>
    <email>crmoresearch@seattlechildrens.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Scheck, BS</last_name>
      <phone>206-987-2000</phone>
      <email>crmoresearch@seattlechildrens.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zhao Y, Wu EY, Oliver MS, Cooper AM, Basiaga ML, Vora SS, Lee TC, Fox E, Amarilyo G, Stern SM, Dvergsten JA, Haines KA, Rouster-Stevens KA, Onel KB, Cherian J, Hausmann JS, Miettunen P, Cellucci T, Nuruzzaman F, Taneja A, Barron KS, Hollander MC, Lapidus SK, Li SC, Ozen S, Girschick H, Laxer RM, Dedeoglu F, Hedrich CM, Ferguson PJ; Chronic Nonbacterial Osteomyelitis/Chronic Recurrent Multifocal Osteomyelitis Study Group and the Childhood Arthritis and Rheumatology Research Alliance Scleroderma, Vasculitis, Autoinflammatory and Rare Diseases Subcommittee. Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. Arthritis Care Res (Hoboken). 2018 Aug;70(8):1228-1237. doi: 10.1002/acr.23462. Epub 2018 Jul 12. Review.</citation>
    <PMID>29112802</PMID>
  </reference>
  <reference>
    <citation>Zhao Y, Ferguson PJ. Chronic Nonbacterial Osteomyelitis and Chronic Recurrent Multifocal Osteomyelitis in Children. Pediatr Clin North Am. 2018 Aug;65(4):783-800. doi: 10.1016/j.pcl.2018.04.003. Review.</citation>
    <PMID>30031498</PMID>
  </reference>
  <reference>
    <citation>Oliver M, Lee TC, Halpern-Felsher B, Murray E, Schwartz R, Zhao Y; CARRA SVARD CRMO/CNO workgroup. Disease burden and social impact of pediatric chronic nonbacterial osteomyelitis from the patient and family perspective. Pediatr Rheumatol Online J. 2018 Dec 14;16(1):78. doi: 10.1186/s12969-018-0294-1.</citation>
    <PMID>30547806</PMID>
  </reference>
  <reference>
    <citation>Beck C, Morbach H, Beer M, Stenzel M, Tappe D, Gattenlöhner S, Hofmann U, Raab P, Girschick HJ. Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment. Arthritis Res Ther. 2010;12(2):R74. doi: 10.1186/ar2992.</citation>
    <PMID>20433730</PMID>
  </reference>
  <reference>
    <citation>Girschick H, Finetti M, Orlando F, Schalm S, Insalaco A, Ganser G, Nielsen S, Herlin T, Koné-Paut I, Martino S, Cattalini M, Anton J, Mohammed Al-Mayouf S, Hofer M, Quartier P, Boros C, Kuemmerle-Deschner J, Pires Marafon D, Alessio M, Schwarz T, Ruperto N, Martini A, Jansson A, Gattorno M; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever registry. The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology (Oxford). 2018 Jul 1;57(7):1203-1211. doi: 10.1093/rheumatology/key058. Erratum in: Rheumatology (Oxford). 2018 Aug 1;57(8):1504.</citation>
    <PMID>29596638</PMID>
  </reference>
  <reference>
    <citation>Voit AM, Arnoldi AP, Douis H, Bleisteiner F, Jansson MK, Reiser MF, Weckbach S, Jansson AF. Whole-body Magnetic Resonance Imaging in Chronic Recurrent Multifocal Osteomyelitis: Clinical Longterm Assessment May Underestimate Activity. J Rheumatol. 2015 Aug;42(8):1455-62. doi: 10.3899/jrheum.141026. Epub 2015 May 15.</citation>
    <PMID>25979713</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Yongdong (Dan) Zhao</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Pamidronate</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Golimumab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

